Article Text

PDF
Falls and health status in elderly women following first eye cataract surgery: an economic evaluation conducted alongside a randomised controlled trial
  1. Tracey H Sach1,
  2. Alexander J E Foss2,
  3. Richard M Gregson2,
  4. Anwar Zaman2,
  5. Francis Osborn2,
  6. Tahir Masud3,
  7. Rowan H Harwood3
  1. 1
    School of Chemical Sciences and Pharmacy, University of East Anglia, Norwich, UK
  2. 2
    Department of Ophthalmology, University Hospital, Queen’s Medical Centre, Nottingham, UK
  3. 3
    Clinical Gerontology Research Unit, City Hospital, Nottingham, UK
  1. Dr Tracey Sach, School of Chemical Sciences and Pharmacy, University of East Anglia, Norwich NR4 7TJ, UK; T.Sach{at}uea.ac.uk

Abstract

Aim: To evaluate the cost-effectiveness of first eye cataract surgery compared with no surgery from a health service and personal social services perspective.

Methods: An economic evaluation undertaken alongside a randomised controlled trial of first eye cataract surgery in secondary care ophthalmology clinics. A sample of 306 women over 70 years old with bilateral cataracts was randomised to cataract surgery (expedited, approximately four weeks) or control (routine, 12 months wait); 75% of participants had baseline acuity of 6/12 or better. Outcomes included falls and the EuroQol EQ-5D.

Results: The operated group cost a mean £2004 (bootstrapped) more than the control group over one year (95% confidence interval (CI), £1363 to £2833) (p<0.001), but experienced on average 0.456 fewer falls, an incremental cost per fall prevented of £4390. The bootstrapped mean gain in quality adjusted life years (QALYs) per patient was 0.056 (95% CI, 0.006 to 0.108) (p<0.001). The incremental cost–utility ratio was £35 704, above the currently accepted UK threshold level of willingness to pay per QALY of £30 000. However, in an analysis modelling costs and benefits over patients’ expected lifetime, the incremental cost per QALY was £13 172, under conservative assumptions.

Conclusions: First eye cataract surgery, while cost-ineffective over the trial period, was probably cost-effective over the participants’ remaining lifetime.

  • economic evaluation
  • cataract surgery
  • falls
  • elderly

Statistics from Altmetric.com

Footnotes

  • Competing interests: None declared.

  • Abbreviations:
    CEAC

    cost-effectiveness acceptability curve

    HRQL

    health related quality of life

    ICER

    incremental cost-effectiveness ratio

    QALY

    quality adjusted life year

    WTP

    willingness to pay

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.